Macrophage therapeutics, inc. wins delaware case against michael goldberg for breach of fiduciary duty

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on june 23, 2021, vice chancellor joseph slights of the court of chancery of the state of delaware (the “court”) ruled in favor of navidea's wholly-owned subsidiary, macrophage therapeutics, inc. (“mt”) and against its former ceo, dr. michael goldberg, finding tha
NAVB Ratings Summary
NAVB Quant Ranking